For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Teneobio, Inc.

USPTO Granted Patents = 14

EPO Patents = 2

Forward Citations = 11

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Nathan D Trinklein (13 out of 22 patents)

Katherine Harris (11 out of 16 patents)

Wim Van Schooten (9 out of 19 patents)

4. Shelley Force Aldred (8 out of 17 patents)

5. Kevin Dang (3 out of 3 patents)

6. Duy Pham (2 out of 5 patents)

7. Udaya Rangaswamy (2 out of 2 patents)

8. Harbani Kaur Malik Chaudhry (2 out of 3 patents)

9. Brian Avanzino (2 out of 2 patents)

10. Karen Chang (2 out of 2 patents)

11. Nicole Allen (2 out of 2 patents)

12. Starlynn Clarke (1 out of 3 patents)

13. James Noble Kochenderfer (1 out of 30 patents)

14. Laura Marie Davison (1 out of 1 patent)

15. Heather Anne N Ogana (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 12735503 - ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES (2026-09-15),

2. 12709644 - ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES (2026-08-18),

3. 12590163 - AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE (2026-03-31),

4. 12570717 - ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS (2026-03-10),

5. 12495776 - TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES (2025-12-16),

6. 12371505 - Anti-BCMA heavy chain-only antibodies (2025-07-29),

7. 12180298 - Heavy chain antibodies binding to PSMA (2024-12-31),

8. 11970540 - Anti-BCMA heavy chain-only antibodies (2024-04-30),

9. 11905326 - Multispecific heavy chain antibodies binding to CD22 and CD3 (2024-02-20),

10. 11884735 - Agonistic anti-IL-2R antibodies and methods of use (2024-01-30),

11. 11873336 - Heavy chain antibodies binding to CD22 (2024-01-16),

12. 11613572 - CD3 binding antibodies (2023-03-28),

13. 11505606 - CD3 binding antibodies (2022-11-22),

14. 11434299 - Anti-BCMA heavy chain-only antibodies (2022-09-06),

Teneobio, Inc. is a biotechnology company focused on the discovery and development of novel biologics for the treatment of cancer and autoimmune diseases. Their innovative platform enables the rapid generation of fully human antibodies with superior specificity and potency. Teneobio's goal is to revolutionize the field of biologics through their cutting-edge technology and collaborative partnerships with leading pharmaceutical companies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

14 Patents

#30 in Newark, CA

#5,305 in California

#22,262 in US

#42,118 in the World

Newark, CA, United States of America

Teneobio, Inc.

Forward Citations = 11

27 inventors:

Nathan D Trinklein (13 out of 22 patents)

Katherine Harris (11 out of 16 patents)

Wim Van Schooten (9 out of 19 patents)

4. Shelley Force Aldred (8 out of 17 patents)

5. Kevin Dang (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…